• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis.

作者信息

Neema Shekhar, Singh Sehdev, Pathak Niloy, Khan M A

机构信息

Department of Dermatology, Command Hospital, Kolkata, West Bengal, India.

出版信息

Indian Dermatol Online J. 2019 Jan-Feb;10(1):76-78. doi: 10.4103/idoj.IDOJ_170_18.

DOI:10.4103/idoj.IDOJ_170_18
PMID:30775308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6362754/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/e9b8c2c7fbe7/IDOJ-10-76-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/7fe161ec9efe/IDOJ-10-76-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/fe8491f9ef74/IDOJ-10-76-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/e9b8c2c7fbe7/IDOJ-10-76-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/7fe161ec9efe/IDOJ-10-76-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/fe8491f9ef74/IDOJ-10-76-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e0/6362754/e9b8c2c7fbe7/IDOJ-10-76-g003.jpg

相似文献

1
Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis.使用司库奇尤单抗治疗慢性斑块状银屑病的患者出现广泛浅表皮肤癣菌病
Indian Dermatol Online J. 2019 Jan-Feb;10(1):76-78. doi: 10.4103/idoj.IDOJ_170_18.
2
Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.司库奇尤单抗在印度中重度斑块状银屑病患者中的疗效和安全性：来自FIXTURE的亚组分析，一项随机、安慰剂对照的3期研究
Indian Dermatol Online J. 2017 Jan-Feb;8(1):16-24. doi: 10.4103/2229-5178.198765.
3
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.使用自动注射器给药司库奇尤单抗在52周内持续减轻斑块状银屑病的严重程度：随机对照JUNCTURE试验的结果
J Eur Acad Dermatol Venereol. 2017 May;31(5):847-856. doi: 10.1111/jdv.14073. Epub 2017 Jan 23.
4
Secukinumab: a review in moderate to severe plaque psoriasis.司库奇尤单抗：治疗中重度斑块状银屑病的研究进展。
Am J Clin Dermatol. 2015 Aug;16(4):323-330. doi: 10.1007/s40257-015-0143-7.
5
Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.司库奇尤单抗治疗斑块状银屑病疗效与安全性的荟萃分析。
Ann Pharmacother. 2016 May;50(5):341-51. doi: 10.1177/1060028015626545. Epub 2016 Jan 18.
6
Secukinumab for treating plaque psoriasis.司库奇尤单抗治疗斑块状银屑病。
Expert Opin Biol Ther. 2016;16(1):119-28. doi: 10.1517/14712598.2016.1121986. Epub 2015 Dec 14.
7
Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.司库奇尤单抗治疗中度至重度斑块状银屑病的疗效和安全性：一项随机对照试验的荟萃分析
Int J Clin Exp Med. 2015 Mar 15;8(3):3156-72. eCollection 2015.
8
Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.用于治疗合并眼部疾病的斑块状银屑病的司库奇尤单抗：临床经验
J Dermatolog Treat. 2018;29(sup1):9-11. doi: 10.1080/09546634.2018.1527995.
9
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在中重度斑块型银屑病患者中显示出最小的免疫原性。
Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.
10
Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.司库奇尤单抗治疗中重度斑块状银屑病的临床与经济学综述
Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):153-66. doi: 10.1586/14737167.2016.1133301. Epub 2016 Feb 2.

引用本文的文献

1
Dermatophyte infection: from fungal pathogenicity to host immune responses.皮肤癣菌感染：从真菌的致病性到宿主的免疫反应。
Front Immunol. 2023 Nov 2;14:1285887. doi: 10.3389/fimmu.2023.1285887. eCollection 2023.
2
Skin Immunity to Dermatophytes: From Experimental Infection Models to Human Disease.皮肤对皮肤癣菌的免疫：从实验感染模型到人类疾病
Front Immunol. 2020 Dec 2;11:605644. doi: 10.3389/fimmu.2020.605644. eCollection 2020.

本文引用的文献

1
IL-17-Mediated Immunity Controls Skin Infection and T Helper 1 Response during Experimental Microsporum canis Dermatophytosis.IL-17 介导的免疫控制实验性犬小孢子菌皮肤感染和 T 辅助 1 反应。
J Invest Dermatol. 2018 Aug;138(8):1744-1753. doi: 10.1016/j.jid.2018.02.042. Epub 2018 Mar 20.
2
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.司库奇尤单抗长期安全性经验：10 项中度至重度斑块型银屑病患者的 II 期和 III 期临床研究汇总分析。
J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.
3
Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.
JAMA Dermatol. 2016 Apr;152(4):486-7. doi: 10.1001/jamadermatol.2015.4992.
4
The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.银屑病性疾病中的Th17轴：发病机制及治疗意义
Auto Immun Highlights. 2014 Jan 22;5(1):9-19. doi: 10.1007/s13317-013-0057-4. eCollection 2014 Jun.
5
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).预充式注射器给药司库奇尤单抗治疗银屑病的疗效、安全性和使用结果：一项随机对照试验（FEATURE）。
Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.
6
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
7
Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia/lymphoma.成人 T 细胞白血病/淋巴瘤中表皮固有免疫缺陷与浅表皮肤癣菌病。
Clin Cancer Res. 2012 Jul 15;18(14):3772-9. doi: 10.1158/1078-0432.CCR-12-0292. Epub 2012 May 30.
8
A peptide antibiotic from human skin.一种来自人类皮肤的肽抗生素。
Nature. 1997 Jun 26;387(6636):861. doi: 10.1038/43088.